1.Coppola M, Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett. 2012;208:12–5.

2.Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2010;24:2706–14.

3.Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-Methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012;8:69–75.

4.Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-Methylenedioxypyrovalerone. Ann Emerg Med. 2012;60:103–5.

5.Zawilska JB, Wojcieszak J. Designer cathinones—an emerging class of novel recreational drugs. Forensic Sci Int. 2013;231:42–53.

6.Kesha K, Boggs CL, Ripple MG, et al. Methylenedioxypyrovalerone (“bath salts”), related death: case report and review of the literature. J Forensic Sci. 2013;58:1654–9.

7.Jerry J, Collins G, Streem D. Synthetic legal intoxicating drugs: the emerging “incense” and “bath salt” phenomenon. Cleve Clin J Med. 2012;79:258–64.

8.Ross EA, Watson M, Goldberger B. “bath salts” intoxication. N Engl J Med. 2011;365:967–8.

9.Regunath H, Ariyamuthu VK, Dalal P, Misra M. Bath salt intoxication causing acute kidney injury requiring hemodialysis. Hemodial Int. 2012;16:S47–9.

10.Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol. 2013;37:135–46.

11.Swortwood MJ, Boland DM, DeCaprio AP. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Anal Bioanal Chem. 2012;405:1383–97.

12.Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol. 2011;49:499–505.

13.Férec S, Bretaudeau-Deguigne M, Lelièvre B, et al. Expositions récréatives de 8 patients aux nouvelles drogues de synthèse obtenues sur Internet : à propos de 3,4-méthylènedioxypyrovalérone (MDPV) et de méthoxétamine (MXE). Ann Toxicol Anal. 2013;25:47–56.

14.Wyman JF, Lavins ES, Engelhart D, et al. Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts.”. J Anal Toxicol. 2013;37:182–5.

15.Kriikku P, Wilhelm L, Schwarz O, Rintatalo J. New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int. 2011;210:195–200.

16.Mugele J, Nañagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med. 2012;60:100–2.

17.Fröhlich S, Lambe E, O’Dea J. Acute liver failure following recreational use of psychotropic “head shop” compounds. Ir J Med Sci. 2011;180:263–4.

18.Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing Flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol. 2012;8:310–3.

19.Penders TM, Gestring R. Hallucinatory delirium following use of MDPV: “Bath Salts.”. Gen Hosp Psychiatry. 2011;33:525–6.

20.Bertol E, Mari F, Boscolo Berto R, et al. A mixed MDPV and benzodiazepine intoxication in a chronic drug abuser: determination of MDPV metabolites by LC–HRMS and discussion of the case. Forensic Sci Int. 2014;243:149–55.

21.Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as “bath salts”--Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60:624–7.

22.Namera A, Urabe S, Saito T, et al. A fatal case of 3,4-methylenedioxypyrovalerone poisoning: coexistence of α-pyrrolidinobutiophenone and α-pyrrolidinovalerophenone in blood and/or hair. Forensic Toxicol. 2013;31:338–43.

23.Young AC, Schwarz ES, Velez LI, Gardner M. Two cases of disseminated intravascular coagulation due to “bath salts” resulting in fatalities, with laboratory confirmation. Am J Emerg Med. 2013;31:445.e3–5.

24.Nichols DE, Frescas S. Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin. Synthesis. 1999;1999:935–8.

25.Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive “bath salts” products. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:552–62.

26.Gill JR. Practical toxicology for the forensic pathologist. In: Tsokos M, editor. Forensic pathology reviews. New Jersey: Humana Press; 2005. p. 243–69.

27.Vilke GM, DeBard ML, Chan TC, et al. Excited delirium syndrome (ExDS): defining based on a review of the literature. J Emerg Med. 2012;43:897–905.

28.Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high-resolution MS and its detectability in urine by GC–MS. J Mass Spectrom. 2010;45:1426–42.